

9. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence DAATPAPP (SEQ ID NO:3).

10. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence PPAATSAPG (SEQ ID NO:4).

11. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence PDTRPAPGATAPPAHGVTS (SEQ ID NO:5).

12. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence PDTRPAPGATAPPAHGVTA (SEQ ID NO:6).

13. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence PDARPAPGATAPPAHGVTA (SEQ ID NO:7).

14. The modified mammalian cells of claim 6, wherein the repeated amino acid sequence comprises or consists of the sequence PDTRPAPGSTAPPAHGVTS (SEQ ID NO:8).

15. The modified mammalian cells of claim 6, wherein said cells are present in a suspension culture.

16. The modified mammalian cells of claim 6, wherein the cells in the suspension exhibit less aggregation relative to a control value obtained from a suspended cell culture comprising cells that do not express the polypeptide comprising the repeated amino acid sequences, and optionally wherein the suspension cell culture is present in a suspended cell bioreactor.

17. The modified mammalian cells of claim 16, wherein the modified mammalian cells further comprise an introduced polynucleotide encoding a distinct polypeptide that is different from the polypeptide comprising the repeated amino acid sequences, and wherein the distinct polypeptide is produced by the modified mammalian cells.

18. The modified mammalian cells of claim 6, wherein the modified mammalian cells are modified human cells, and wherein O-glycans on the segment external to the cells comprise one or a combination of Core 2 O-glycan,

GlcNAcQ β 1-6(Gal β 1-3)GalNAc and/or the Core 2 derivatives of GlcNAc β 1-6(Gal β 1-3)GalNAc at an abundance of at least 5% relative to all Core 1, Core 2, Core 3, Core 4, Core 5, Core 6, Core 7, and Core 8 O-glycans.

19. The modified mammalian cells of claim 6, wherein the transmembrane anchor comprises a cytoplasmic recycling motif.

20. An isolated polynucleotide encoding a polypeptide comprising a transmembrane anchor and a repeated amino acid sequences according to claim 6.

21. The isolated polynucleotide of claim 20, wherein the isolated polynucleotide is present in an expression vector for use in integration of the sequence encoding the polypeptide into a chromosome of mammalian cells.

22. A method of making cells that express a polypeptide according to claim 6, comprising introducing an isolated polynucleotide into the cells such that the polypeptide is expressed.

23. A method for producing a desired polypeptide, the method comprising expressing the desired polypeptide in modified mammalian cells according to claim 6, such that the desired polypeptide is produced, wherein the desired polypeptide is distinct from the polypeptide comprising the repeated amino acid sequences.

24. The method of claim 23, further comprising separating the desired polypeptide from the suspension cell culture.

25. The method of claim 24, wherein the modified mammalian cells are adapted to growth in a suspension culture.

26. A polypeptide produced by introducing into modified mammalian cells according to claim 6 such that the polypeptide is expressed and separated from the modified mammalian cells, and wherein the polypeptide that is separated comprises an amino acid sequence that is different from the polypeptide comprising the repeated amino acid sequences.

27. A cell suspension bioreactor comprising a suspension cell culture comprising modified mammalian cells according to claim 6.

* * * * *